Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder

NCT03854578 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03854578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03854578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
March 12, 2019
Completion date
September 23, 2019
Enrollment
73 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major